Skip to main content

Table 3 Logistic regression analyses of risk factors for one-year radiographic progression

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

 

OR

95% CI

p value*

Univariate analyses

 Female

0.845

(0.373–1.915)

0.687

 Age

0.993

(0.969–1.018)

0.598

 Disease duration

1.004

(1.000–1.008)

0.076

 CHB status

3.129

(1.661–5.895)

<0.001

 TJC28

0.996

(0.934–1.063)

0.914

 SJC28

0.982

(0.908–1.062)

0.651

 Pain VAS

1.056

(0.905–1.232)

0.491

 PtGA

1.094

(0.939–1.274)

0.248

 PrGA

1.086

(0.921–1.281)

0.326

 HAQ

1.346

(0.990–1.830)

0.058

 CRP

1.001

(0.998–1.014)

0.876

 ESR

0.999

(0.989–1.008)

0.786

 RF positivity

2.355

(0.921–6.023)

0.074

 ACPA positivity

1.983

(0.775–5.070)

0.153

 DAS28-CRP

1.011

(0.742–1.378)

0.944

 MMP-3

1.001

(0.999–1.002)

0.292

 mTSS

1.016

(1.006–1.026)

0.001

 Treatment-naïveb

0.710

(0.365–1.381)

0.313

 GCs

2.300

(0.964–5.489)

0.061

 MTX

1.369

(0.330–5.678)

0.666

 LEF

0.684

(0.359–1.304)

0.248

 SSZ

1.984

(0.876–4.495)

0.101

 HCQ

1.611

(0.828–3.135)

0.160

 CysA

1.591

(0.490–5.167)

0.440

 Iguratimod

1.130

(0.348–3.670)

0.839

 Biologic agents

0.477

(0.200–1.139)

0.095

 MTX combined with SSZ and HCQ

2.265

(0.949–5.406)

0.066

 MTX combined with LEF

0.719

(0.384–1.346)

0.302

 One-year cumulative dose of GCsc

1.000

(1.000–1.000)

0.010

 One-year cumulative dose of MTX

0.999

(0.998–1.000)

0.224

 One-year cumulative dose of LEFd

1.000

(1.000–1.000)

0.074

 One-year cumulative dose of SSZ

1.001

(1.000–1.003)

0.133

 One-year cumulative dose of HCQ

1.004

(0.998–1.009)

0.160

 One-year cumulative dose of CysAe

1.000

(1.000–1.000)

0.124

 One-year cumulative dose of iguratimodf

1.000

(1.000–1.000)

0.761

 One-year cumulative dose of tocilizumabg

1.000

(0.999–1.000)

0.232

 One-year cumulative dose of Yi Sai Pu

1.000

(0.998–1.003)

0.817

 One-year cumulative dose of infliximab

0.997

(0.989–1.006)

0.564

Bivariate models

 CHB status adjusted for baseline mTSS

2.610

(1.338–5.092)

0.005

 CHB status adjusted for one-year cumulative dose of GCs

2.881

(1.511–5.493)

0.001

Multivariate model

 CHB status adjusted for baseline mTSS and one-year cumulative dose of GCs

2.403

(1.218–4.743)

0.011

  1. ACPA anti-cyclic citrullinated peptide antibody, CHB chronic hepatitis B virus (HBV) infection, CI confidence interval, CRP C-reactive protein, CysA cyclosporin A, DAS28 Disease Activity Score 28-joint assessment, ESR erythrocyte sedimentation rate, GC glucocorticosteroid, HAQ Stanford Health Assessment Questionnaire, HCQ hydroxychloroquine, LEF leflunomide, mTSS modified total Sharp score, MTX methotrexate, OR odds ratio, Pain VAS pain visual analog scale, PrGA provider global assessment of disease activity, PtGA patient global assessment of disease activity, RF rheumatoid factor, SJC28 28-joint swollen joint count, SSZ sulfasalazine, TJC28 28-joint tender joint count
  2. aCalculated using conditional logistic regression analysis. Univariate logistic regression analysis was performed on variables, including baseline characteristics, CHB status, and rheumatoid arthritis medications after enrollment (including categories of medications, one-year cumulative doses of medications, and different regimens of combined therapies); bivariate analysis was performed by adjusting for baseline mTSS and one-year cumulative dose of GCs respectively; multivariate logistic regression analysis was performed by adjusting for all significant univariate factors: bold p values are significant
  3. bWithout glucocorticosteroid or DMARD therapy for 6 months before enrollment
  4. cOne-year cumulative dose of GCs: OR 1.000282, 95% CI 1.000067–1.000497; p = 0.010
  5. dOne-year cumulative dose of LEF: OR 0.999888, 95% CI 0.999766–1.000011; p = 0.074
  6. eOne-year cumulative dose of CysA: OR 1.000025, 95% CI 0.999993–1.000057; p = 0.124
  7. fOne-year cumulative dose of iguratimod: OR 1.000013, 95% CI 0.999926–1.000101; p = 0.761
  8. gOne-year cumulative dose of tocilizumab: OR 0.999719, 95% CI 0.999259–1.000180; p = 0.232